#USA #Austin #Medical Research #Allergan Aesthetics #Weight Loss Medications

Allergan Aesthetics Unveils New Clinical Data

Allergan Aesthetics, a part of AbbVie, recently revealed promising findings from two focused clinical studies examining skincare routines in conjunction with DiamondGlow® dermabrasion treatments. These studies, targeting individuals undergoing medical weight loss therapy utilizing glucagon-like peptide-1 receptor agonists (GLP-1 RAs), showcased noteworthy improvements in skin quality. The results were presented at the prestigious Science of Skin Summit (SSS) held from September 17-20, 2026, in Austin, Texas.

Clinical Study Overview

The two studies assessed the effects of a targeted skincare regimen comprising a growth factor serum, neck cream, and a firming body lotion. The first study lasted for 12 weeks and included nine participants, while the second study was a six-week regimen that involved 11 participants who underwent at least one post-treatment evaluation.

Key Findings

1. Significant Improvements:
- In the 12-week study, significant improvements in dryness, skin tone evenness, and other skin quality measures were visible as soon as week two.
- The six-week study showed immediate enhancements in skin quality after DiamondGlow® treatments.

2. Participant Satisfaction:
- Participants consistently reported high satisfaction levels regarding the treatment's efficacy. Various metrics received positive feedback, showcasing the varying impacts based on treatment areas and methodologies.

3. Youthful Perception:
- Participants in the first study felt their facial skin appeared approximately 10 years younger after four weeks of using the growth factor serum twice daily. Meanwhile, those in the secondary study noted their skin looked about 7.5 years younger following three DiamondGlow® treatments.

Insights from Experts

Elizabeth Makino, director of clinical development and scientific affairs at Allergan Aesthetics, emphasized the need to comprehend the skin's changes related to medical weight loss therapies. She noted that these findings contribute to the clinical evidence regarding targeted skincare and noninvasive approaches for individuals on medical weight loss medications. As patient needs evolve, further research involving larger groups is anticipated to clarify these initial insights.

Posters and Presentations

During the Science of Skin Summit, digital posters from both studies were showcased on touchscreen monitors. These presentations contributed to ongoing scientific discussions about the relationship between weight loss medications and skin quality improvements.

Presentations Included:

• - Skin Quality Improvements With a Skincare Regimen in Individuals Taking Medical Weight Loss Medication
• - Skin Quality Improvements With Dermabrasion and a Skincare Regimen in Individuals Taking Medical Weight Loss Medication

Conclusion

The clinical data presented by Allergan Aesthetics marks a significant point in understanding the interplay between weight loss treatments and skin health. As the aesthetics field evolves, companies like Allergan Aesthetics are at the forefront, striving to address both the health and aesthetic concerns of their patients effectively. The results from these studies not only highlight the advancements in skincare but also set the stage for future exploration into treatments that cater to a comprehensive view of patient wellness.

With a commitment to providing innovative solutions, Allergan Aesthetics continues to explore the synergy between medical advancements and aesthetic improvements to meet the evolving needs of clients. For further details on Allergan Aesthetics and their innovative portfolio, visit www.allerganaesthetics.com.